47 results about "Pigmented Epithelium" patented technology

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.

The invention relates to the technical field of retina analysis, and discloses a fundus optical coherence tomography image feature point automatic positioning method, which comprises the following steps: acquiring optical coherence tomography images of a fundus disease patient at different disease course stages, constructing an image database containing a training set and a verification set, and determining the feature points of the fundus optical coherence tomography image on the basis of the image database. And carrying out feature layer segmentation on the image by adopting a U-Net convolutional neural network. And determining a blood vessel shadow position in the fundus optical coherence tomography image and acquiring a boundary of the blood vessel shadow position based on the pigment epithelium gray scale curve. And determining the position of a seed point and the size of a subarea by combining an important layer boundary and a vessel shadow boundary, and assisting digital image correlation to realize retina full-field deformation measurement. According to the method, through deep fusion of deep learning and an image processing technology, the problem of automatic selection of the seed points in the fundus OCT image is solved, the efficiency, precision and reliability of retinal deformation measurement are remarkably improved, and a powerful technical tool is provided for mechanism research and clinical diagnosis and treatment of fundus diseases.

To provide a pharmaceutical composition for restoring lysosomal function of retinal pigment epithelial cells.SOLUTION: Provided is a pharmaceutical composition for restoring lysosomal function of retinal pigment epithelial (RPE) cells in a subject, comprising a polypeptide comprising βA1-crystallin or a nucleic acid encoding the polypeptide.SELECTED DRAWING: Figure 1

The invention belongs to the field of RPE cell preparations, and relates to a retinal pigment epithelial cell spherical preparation which is obtained by the following steps: step 1, obtaining RPE cells; and 2, inoculating the RPE cells into a cell culture plate by using an inoculation culture medium, and culturing after centrifugal precipitation, so that a plurality of RPE cells are aggregated to form RPE cell balls with uniform sizes. The cell preparation form obtained by the scheme not only can avoid injection leakage of the subretinal space, but also has the advantages of being convenient to inject and uniform in cell expansion, so that preclinical needs are met, and an important basis is provided for preparation of a clinical-grade RPE cell preparation and subsequent further development of clinical research.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

The invention discloses application of a DKK1 inhibitor in preparation of a medicine for treating dry age-related macular degeneration. According to the application disclosed by the invention, the expression of DKK1 in dry AMD cells and animal models induced by sodium iodate (NaIO3) is obviously improved. The form of the retinal pigment epithelial cells can be protected and the death rate can be reduced by using the siRNA of the targeted DKK1 in an in-vitro experiment, and the plaque loss of the retinal pigment epithelial cells can be relieved and the retinal pigment epithelial cells can be protected by using the shRNA of the targeted DKK1 in an in-vivo experiment. Therefore, the invention provides a new therapeutic target and therapeutic strategy for dry AMD, and has important clinical application value.

The present invention relates to a composition for preventing and alleviating or treating glaucoma and macular degeneration, containing a Centella asiatica extract. Particularly, the composition increases the glucose metabolism efficiency of cells so as to increase the survival rate of retinal neurons and pigment epithelial cells and protects cells from oxidative damage caused by A2E, thereby being effectively usable as a composition for eye health and for preventing and alleviating or treating glaucoma and macular degeneration.

Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity / efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.

The present invention provides a method for preparing retinal pigment epithelial cells, comprising (1) a first step of subjecting pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells, (2) a second step of subjecting the aggregates of the pluripotent stem cells to suspension culture in a serum-free medium to form aggregates of the pluripotent stem cells. (1) a third step in which the aggregate formed in step (1) is subjected to suspension culture in a serum-free medium or a serum-containing medium, each of which does not contain a substance acting on the Sonic hedgehog signal transduction pathway and contains a substance acting on the BMP signal transduction pathway, to obtain an aggregate containing retinal progenitor cells; the aggregate formed in step (2) is subjected to suspension culture in a serum-free medium or a serum-containing medium that does not contain a substance that acts on the Sonic hedgehog signal transduction pathway and a substance that acts on the BMP signal transduction pathway, but contains a substance that acts on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithelium cells.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

The present invention is directed to compositions for treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells by contacting orbital fat-derived mesenchymal cell with the damaged RPE cells.

The invention discloses an application of CRX in inhibition of epithelial-mesenchymal transition of retinal pigment epithelial cells. The invention discloses an application of CRX in preparation of a medicine as shown in (1) or (2). The medicine comprises a carrier for over-expressing CRX; (1) a drug for inhibiting epithelial-mesenchymal transition of retinal pigment epithelial cells; and (2) a medicine for preventing and / or treating age-related macular degeneration subretinal fibrosis. The invention finds that the expression of E-cadherin and Occludin can be promoted by overexpressing CRX in RPE cells, so that the epithelial-mesenchymal transition of the RPE cells is inhibited, and the CRX can be used for preventing or treating age-related macular degeneration subretinal fibrosis and also can be used for preventing or treating highly myopia retinal degeneration.

The invention belongs to the field of natural products, and provides chrysanthemum essential oil with a function of improving dry age-related macular degeneration. The chrysanthemum essential oil contains up to 168 compounds, more comprehensive biological activity support is provided for treatment, experiments prove that the essential oil can significantly optimize the retina structure of macular mice, specifically, the inner nuclear layer and the outer nuclear layer are closely arranged, the total thickness of the retina is significantly increased, the retinal pigment epithelium is more closely arranged, and the effect of improving the retina structure is achieved. Therefore, the polypeptide has the potential of improving the dry age-related macular degeneration function.

The invention relates to a compatibility method of a retinal pigment epithelial cell cryopreservation preparation, which comprises the steps of dilution, balancing, washing and compatibility: 1) a dilution step: preparing a diluted solution which comprises a balanced salt solution (for perfusion), preferably, the diluted solution further comprises a compound amino acid injection; 2) a balancing step: resuscitating cells in the RPE cell cryopreservation preparation, then mixing the cells with the prepared diluted solution, and standing for balancing; (3) washing: centrifuging the solution, absorbing and discarding the supernate, adding a balanced salt solution (for perfusion), resuspending the cells, centrifuging, and absorbing and discarding the supernate; and 4) a compatibility step: adding a balanced salt solution (for perfusion) into the cell precipitate, and adjusting the cell to a required density according to a living cell density result.

The recombinant AAV capsid protein is characterized in that the recombinant AAV capsid protein is obtained by mutating a common region of natural AAV5 capsid proteins VP1, VP2 and VP3; or the natural AAV5 capsid protein is heterozygous with other AAV serotype capsids, and then a common region of VP1, VP2 and VP3 is mutated, wherein the mutation point corresponds to at least one mutation from the 310th site to the 736th site of the AAV5 capsid protein of SEQ ID NO: 1; the capsid protein is targeted to the retinal pigment epithelium through intravitreal delivery, the problems that in the prior art, delivery is difficult, and retinal pigment epithelium cells cannot be effectively transduced are solved, and the AAV capsid protein has high transduction rate and immune escape capacity.

Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for administration to the eye for treatment of diseases, disorders, and conditions of the eye, particularly for diseases, disorders, and conditions that involve tissues and cells in the back of the eye, which generally cannot be treated with eyedrops. Upon administration to the eye, the MEVs deliver therapeutics to tissues that include the choroid, retinal pigment epithelium cells, and photoreceptor cells. The compositions contain extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo for treating or diagnosing or monitoring a disease, disorder, or condition of the eye or involving the eye. Methods of treatment of diseases, disorders, and conditions of the eye are provided.

The present invention relates to a method for identifying and detecting the expression of biomarkers present in choroidal and retinal pigmented epithelium disorders or in ocular angiogenic, epithelial and neuronal disorders. The invention further encompasses a kit for biomarker identification and uses thereof. The present invention pertains to the field of chemical biology, more specifically in the healthcare sector, and describes a method for identifying and detecting the expression of a set of biomarkers present in severe ophthalmological diseases.

To provide compositions for protecting retina which can protect retinal pigment epithelial cells from the damage of active oxygen more effectively and inhibit retinopathy.SOLUTION: A composition for protecting retina contains as active ingredients astaxanthin and at least one ingredient selected from the group consisting of Ipomoea batatas young-leaf processed materials, Pueraria montana flower processed materials, Vaccinium myrtillus processed materials, gallic acid, glutamic acid, histidine, methionine, serine, tyrosine, valine, vitamin B6, vitamin B12, vitamin C, vitamin D3, vitamin K, a calcium compound, a zinc compound, an iron compound, a molybdenum compound, a chromium compound, and shellac.SELECTED DRAWING: Figure 1

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

A method for reinforcing a cellularized retinal construct fabricated from (i) endothelial cells; (ii) retinal pigment epithelial cells and / or photoreceptors; and (iii) an extracellular matrix (ECM) hydrogel is disclosed. The method comprises contacting the construct with a biocompatible small-molecule reinforcing agent that is capable of chemically interacting with the ECM hydrogel under conditions that maintain viability of the cells, to thereby increase a compressive modulus of the ECM hydrogel by at least 10%.

Disclosed are methods for preparing retinal pigment epithelium (RPE) cells from pluripotent stem cells (PSCs). More particularly, it represents an automated method that combines in a sequential manner three differentiating agents to direct the differentiation of human PSCs into RPE cells.

This application relates to a method for inducing stem cells to differentiate into retinal pigment epithelial cells (RPE), comprising the following steps: culturing the pluripotent stem cells in a first culture medium before the pluripotent stem cells exhibit cell state decline after cell culture, wherein the first culture medium comprises DMEM medium, serum, β-mercaptoethanol, non-essential amino acids (NEAA), and L-glutamine. The method described in this application can significantly improve the efficiency of differentiation into RPE.

This invention discloses a method for inducing differentiation and preparing retinal pigment epithelial cells (iPSCs), comprising: treating iPSCs with a first-stage induction differentiation medium, changing the medium daily; discarding the medium, adding a second-stage induction differentiation medium, treating the cells again, changing the medium daily, and picking the cells into matrix gel-coated well plates; discarding the medium, adding a third-stage induction differentiation medium, allowing the cells to adhere, changing the medium again, and allowing the cells to proliferate and grow during this period, while removing contaminating cells. This invention achieves the directed differentiation of iPSCs into retinal pigment epithelial cells through different stages of induction; this method uses a novel culture medium formulation, providing a new approach and method for stem cell differentiation and directed culture.

The invention relates to the technical field of biology, in particular to a PEDF mutant targeting VEGFR2 (vascular endothelial growth factor receptor 2) and application of the PEDF mutant in fundus neovascularization diseases. The sequence of the PEDF mutant of the targeted VEGFR2 is as shown in SEQ ID NO: 1. The invention provides a single injection recombinant adeno-associated virus (rAAV) gene therapy, which is used for treating VEGF (vascular endothelial growth factor) related eye diseases. The therapy prevents neovascularization by inducing expression of a mutant pigment epithelium-derived factor (PEDF). The method comprises the following steps: firstly, establishing two animal models of fundus neovascularization diseases, namely an extremely low density lipoprotein receptor gene knockout (Vldlr <- / ->) mouse model and an oxygen-induced ischemic retinopathy (OIR) mouse model; subsequently, anti-angiogenesis factors are injected into a vitreous cavity, and the result shows that clinically remarkable vasculopathy is almost completely inhibited in the established mouse fundus neovascularization model.

The present disclosure provides a method for obtaining RPE (retinal pigment epithelium) cells from iPSCs (induced pluripotent stem cells). The method involves: (a) generating embryoid bodies from a culture of iPSCs, in which the embryoid bodies are in non-adherent suspension culture, (b) plating the embryoid bodies on a culture dish coated with a suitable extracellular matrix in differentiation induction media (DIM), in which the DIM contains at least one WNT pathway inhibitor and at least two SMAD pathway inhibitors, (c) culturing the neuroectoderm lineage in differentiation propagation media (DPM) for rosette formation, (d) culturing the rosettes of step (c) in Retinal Pigment Epithelium Maturation Media (RPEMM) to facilitate retinal progenitor cells formation, and (e) plating the retinal progenitor cells of step (d) on a culture dish coated with suitable extracellular matrix in RPEMM to obtain RPE cells.

The present invention discloses the use of theaflavin 3'-monogallate in inhibiting retinal pigment epithelial cell apoptosis and treating age-related macular degeneration (AMD), belonging to the field of biomedicine. Specifically, the invention discovers that theaflavin 3'-monogallate has the function of inhibiting retinal pigment epithelial cell apoptosis and promoting the inhibition of retinal pigment epithelial cell proliferation. Furthermore, the invention also discovers that theaflavin 3'-monogallate has the novel function of inhibiting AMD-like lesions caused by retinal pigment epithelial cell apoptosis. Therefore, it can be used to treat AMD, bringing good news to elderly blind patients in China.

High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.

This invention relates generally to Anelloviridae family vectors (e.g., anellovectors) and compositions and uses thereof. The Anelloviridae family vectors can be used, e.g., to deliver an exogenous effector to the retinal pigmented epithelium (RPE) of a subject. In some embodiments, the vectors can be used to treat age-related macular degeneration (AMD).

The present application relates to a novel compound and its use as therapeutically active substance in the treatment and / or prevention of diseases which involve the retinal pigment epithelium, in particular diseases which lead to atrophy, degeneration or death of the retinal pigment epithelium, which can also lead to atrophy or loss of photoreceptors and / or retinal neovascularization.

The invention discloses application of TAPI-1 in preparation of a medicine for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. Sodium iodate is used for constructing a dry age-related macular degeneration mouse model, a TAPI-1 solution is injected into a vitreous body for treatment, and a mouse is subjected to structural examination and histopathological detection. Experimental results show that compared with a control group, the retina-choroid structure of a mouse treated by the TAPI-1 is more complete, fundus lesion areas are fewer, the damage degree of pigment epithelium and photoreceptor cells is lighter, the expression level of inflammatory molecules in eye tissues is lower, and the TAPI-1 has a remarkable treatment effect. The application of the TAPI-1 in preparing the medicine for treating and / or preventing the dry age-related macular degeneration is provided for the first time, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.